ORLANDO, Fla. & SAN FRANCISCO–(BUSINESS WIRE)–Axcel Learning, a professional education platform backed by Alpine Investors…
Company announcement – No. 24 / 2023 Total number of shares and voting rights in…
IRVINE, Calif., May 31, 2023 (GLOBE NEWSWIRE) — Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical…
SEATTLE, May 31, 2023 (GLOBE NEWSWIRE) — Umoja Biopharma, Inc., a transformative immuno-oncology company creating…
PHILADELPHIA, May 31, 2023 (GLOBE NEWSWIRE) — Enterin Inc., a privately held, Philadelphia-based, clinical-stage biopharmaceutical company…
Fremont, California, May 31, 2023 (GLOBE NEWSWIRE) — Omicsveu, The Spatial Multiplex Multiomics Company, announced…
FARMINGDALE, New York, May 31, 2023 (GLOBE NEWSWIRE) — DepYmed, Inc. (“DepYmed” or the “Company”)…
The proportion of acute cerebral ischemic stroke patients with the mRS of 0-2 on day…
HOLLISTON, Mass., May 31, 2023 (GLOBE NEWSWIRE) — Biostage, Inc. (OTCQB: BSTG) (“Biostage” or the “Company”),…
VANCOUVER, British Columbia, May 31, 2023 (GLOBE NEWSWIRE) — Rakovina Therapeutics Inc. (TSX-V: RKV, the…
SAN MATEO, Calif., May 31, 2023 (GLOBE NEWSWIRE) — CARGO Therapeutics, Inc. (CARGO), a biotechnology…
SAN MATEO, Calif., May 31, 2023 (GLOBE NEWSWIRE) — CARGO Therapeutics, Inc. (CARGO), a biotechnology…
Phase 1/2 SLO-RP trial completed target enrollment of 48 patients diagnosed with RP associated with…
Phase 1/2 SLO-RP trial completed target enrollment of 48 patients diagnosed with RP associated with…
Company receives highest average rating across all 26 performance attributes out of 34 CROs included…
Company receives highest average rating across all 26 performance attributes out of 34 CROs included…
Once granted, this patent will provide intellectual property protection until December 2040, and may qualify…
Once granted, this patent will provide intellectual property protection until December 2040, and may qualify…
BURLINGAME, Calif., May 31, 2023 (GLOBE NEWSWIRE) — Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical…
BURLINGAME, Calif., May 31, 2023 (GLOBE NEWSWIRE) — Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical…